“This IND filing represents an important milestone for Lion as we focus on expanding clinical applications of our core TIL technology,” said Elma Hawkins, PhD, Lion’s president and chief executive officer. “In a study conducted and published by the National Cancer Institute, TIL have demonstrated encouraging anti-tumor activity in cervical cancer with two patients showing durable, complete remissions out of nine patients. We are excited to be developing potentially new treatment options in these critical indications.”
About Lion Biotechnologies
Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company’s lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) for the treatment of patients with refractory metastatic melanoma, and is based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and Moffitt Cancer Center. For more information, please visit http://www.lionbio.com.
Forward Looking Statements
This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties described in the Company’s most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations The Trout Group Elizabeth Broder 646-378-2945 [email protected]